Emerging proteomic technologies using novel affinitybased reagents allow for efficient multiplexing with high-sample throughput. To identify early biomarkers of myocardial injury, we recently applied an aptamer-based proteomic profiling platform that measures 1129 proteins to samples from patients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned myocardial injury. Here, we examined the scalability of this approach using a markedly expanded platform to study a far broader range of human proteins in the context of myocardial injury.
O
bstacles for comprehensive blood proteomic profiling include the immense size and structural heterogeneity of circulating proteins, as well as the broad range of abundance levels. [1] [2] [3] Applications of mass spectrometry-based profiling to plasma are limited by complex analytic steps that severely restrict sample throughput. 4 By contrast, multiplexing of targeted methods based on capture and detection of specific proteins may afford advantages for large-scale efforts to characterize human samples. However, many antibody-based assays are limited by cross-reactivity, which precludes large-scale multiplexing. 5 To address this limitation, investigators have turned to alternative affinity-based reagents, including DNA aptamers. Whether aptamer reagents are well suited for efficient multiplexing of thousands of proteins at highsample throughput remains to be tested. As a proof of principle, we recently applied a proteomic profiling platform with multiplexed aptamers 6 to samples from patients undergoing septal alcohol ablation for hypertrophic cardiomyopathy. 6 This human model of planned myocardial injury (PMI), in which each individual serves as his or her own biological control, reproduces key clinical features of spontaneous MI (SMI), including chest pain, electrocardiographic changes and wall motion abnormalities, and the release of established markers of myocardial injury. 7, 8 On screening 1129 proteins on the original platform, we validated 79 proteins that changed in the context of MI. Here we tested the scalability of this approach with a markedly expanded platform containing ≈5000 aptamers targeting a far broader range of analytes. The expanded platform measures many intracellular proteins not previously assayed in the blood, as well as many low-abundance-secreted proteins not previously targeted by aptamer-based reagents. Thus, the substantially expanded platform provides an unprecedented opportunity for novel discovery of proteins that are altered after MI.
METHODS
A complete list of all proteins that change significantly after PMI are included in Table I in the online-only Data Supplement; a complete list of proteins that differ between patients with SMI and controls is included in Table 1 and Table II in the online-only Data Supplement. The analytic methods will be made available to other researchers for the purposes of reproducing the results or replicating the procedure. However, a subset of the study materials (eg, DNA aptamers) is proprietary to Novartis and Somalogic, and investigators are encouraged to contact the corresponding principal investigators for questions.
Human Studies Participants
A total of 35 patients undergoing PMI using alcohol septal ablation for the treatment of symptomatic hypertrophic cardiomyopathy were included in this study (20 in the derivation cohort, 15 in a distinct validation cohort). Inclusion criteria for this cohort and details of the procedure have been previously described. [9] [10] [11] Blood was drawn at baseline, 10 minutes, 1 hour, and 24 hours after injury. To determine the effects of the catheterization procedure alone, including heparin administration, we studied 10 individuals who underwent cardiac catheterization without MI as controls (8 patients undergoing cardiac catheterization for patent foramen ovale closure and 2 patients undergoing cardiac catheterization for PMI who did not undergo septal ablation for anatomic reasons).
We also enrolled 20 patients undergoing emergent cardiac catheterization for acute ST-segment elevation SMI within 8 hours of symptom onset. Femoral venous blood samples were obtained in the coronary catheterization suite on initial presentation. Peripheral blood samples from 43 at-risk patients with negative standard Bruce protocol exercise tests were used as controls for SMI. 12 All blood samples were collected in K2-EDTA-treated tubes, centrifuged within 15 minutes at 2000g for 10 minutes to pellet cellular elements, and subsequently stored at −80°C.
Human study protocols were approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Informed consent was obtained from all participants.
Clinical Perspective
What Is New?
• Like antibodies, DNA aptamers can be generated as affinity reagents for proteins.
• Emerging data suggest that they can be used to measure blood protein levels in clinical cohorts; however, the technology remains in its infancy.
• Here we tested the scalability of this approach with a markedly expanded platform containing ≈5000 aptamers targeting a far broader range of analytes than previously examined using this technology.
• We applied the platform to a cohort of individuals undergoing planned myocardial injury for hypertrophic cardiomyopathy.
• In addition to confirming findings from prior studies, we identified ≈150 additional putative markers of myocardial injury.
What Are the Clinical Applications?
• Our study suggests that the platform can be applied to identify early markers of myocardial injury.
• Such markers might hasten the diagnosis of myocardial injury, as well as the administration of appropriate therapy.
• Our data also provide new insights into the human response to injury as well as new potential targets for therapeutic intervention.
• The improvements in breadth and throughput of this new platform suggest that it can be applied to large patient cohorts to address a variety of important clinical questions. 
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Proteomic Assay Overview
Statistical Analyses
For the PMI studies, all protein values were log-transformed because of nonnormal distributions as determined by the Kolomogorov-Smirnov and Shapiro-Wilk normality tests. For the PMI and cardiac catheterization control studies, 1-way repeated measures analysis of variance was used to test differences in protein levels across time points (baseline, 10 minutes, 1 hour, and 24 hours). All reported P values are global P values (ie, indicating whether protein levels change significantly between baseline and any of the time points). The multivariate adjustment was used if sphericity was violated. In the derivation cohort, we used a Bonferronicorrected P threshold <1.05E-05 (0.05/4783 proteins unaffected in control catheterization) and repeat Bonferronicorrected P threshold <1.33E-04 (0.05/376) aptamers in the PMI validation cohort. For the SMI case-control analysis, a Wilcoxon rank-sum test was used with a Bonferronicorrected P threshold <6.17E-04 (0.05/81 validated proteins shown to increase within 1 hour after MI in the PMI cohort). 
RESULTS
Protein Changes in Peripheral Plasma of Patients With PMI
To first assess reproducibility of the platform, we embedded pooled plasma control samples within and across experimental plates to document intra-and interexperimental CVs. The intra-and interassay CVs (applying performance characteristics for 95% of the probe content in plasma) were 7.45 and 6.49, respectively. Interassay CVs were based on plates that were run ≤21 days apart. To assess biological variability, we compared 2 plasma samples from normal controls collected 10 minutes apart (n=12), which yielded a median intraclass correlation of 0.86 across the entire analytes assayed.
Clinical characteristics of the study patients with PMI are detailed in Table III in the online-only Data Supplement. Using each individual as his or her own biological control, we performed proteomic profiling at baseline, 10 minutes, 1 hour, and 24 hours after injury. We identified 376 proteins that were significantly changed within 24 hours after injury in a derivation cohort of 20 patients (Bonferroni-adjusted P<1.05E-05, 1-way repeated measures analysis of variance). It is important to note that we identified 2027 aptamer-protein pairs that were influenced by the catheterization procedure alone with similar directional changes in PMI, likely because of heparin treatment (nominal P<0.05). These proteins were therefore excluded from the analyses because of possible confounding effects. In a validation cohort of 15 patients, changes in 247 proteins exceeded a repeat Bonferroni threshold (P<1.33E-04, 1-way repeated measures analysis of variance). Ninety percent of the protein changes seen in the derivation cohort was directionally consistent and reached at least nominal significance (P<0.05) in the smaller validation cohort. Table 2 details a subset of the proteins found to be significant in both derivation and validation cohorts that increased by >30% within 10 minutes after PMI in both cohorts. All validated proteins are listed in Table I in the online-only Data Supplement (see Table IV in the online-only Data Supplement for clinical characteristics of the catheterization controls).
The kinetic changes of several representative proteins are illustrated in the Figure. Using the expanded platform, we confirmed increases in well-established clinical markers of MI, including troponin I and CK-MB, as well as other biomarkers previously identified by our group and others such as fatty acid-binding protein 13, 14 and malate dehydrogenase 1. 6 Many of these protein changes were novel in the context of early MI (see Table 2 and Table I in the online-only Data Supplement), including a mitochondrial ATP synthase F 0 subunit component, 15 mitochondrial 2-4-dienoyl-CoA reductase 1 that is important in fatty acid beta oxidation, 16 and muscle-specific adenylosuccinate synthase 1, which plays a role in purine nucleotide metabolism.
17
Validation of Candidate Protein Markers in Spontaneous Myocardial Infarction
To better establish the clinical relevance of the observed changes, we profiled a cohort of patients with SMI (n=20), as well as at-risk individuals without ischemia as determined by exercise stress testing (n=43) (clinical characteristics in Table IV in the online-only Data Supplement). Because the timing of sample collection relative to SMI onset was variable (6.0±1.9 hours), we focused on the PMI-derived candidate protein markers that were elevated within 1 hour after injury, the time point in the PMI series closest to the time of SMI presentation. Of the 81 proteins that were significant and elevated within 1 hour after PMI in both the derivation and validation cohorts, 29 were also elevated in SMI (repeat Bonferroni adjusted P<6.17E-04; Wilcoxon Rank-Sum) ( Table 1) . Among the many novel findings that were concordantly increased in both PMI and SMI were adenylosuccinate synthase 1, ATP synthase F 0 subunit component, dienoyl-CoA reductase 1 as discussed, as well as coiled-coil-helix-coiled-coil-helix domaincontaining 10, a mitochondrial protein that may play a role in oxidative phosphorylation, 18 and cysteine-and glycine-rich protein 3, a muscle LIM domain protein.
Representative data for known biomarkers and several novel proteins are demonstrated in the Figure. In additional exploratory analysis, we also compared SMI versus control samples without filtering for proteins that were changed in PMI. This analysis yielded an additional 58 proteins elevated in SMI versus the control cohort (Table II in the online-only Data Supplement), which included the rediscovery of IL1RL1(ST2), as well as many novel proteins, including the mitochondrial iron-sulfur cluster assembly factor BolA family member 3 and the chloride intracellular channel 4.
Technical Validation by Mass Spectrometry
To rigorously verify the specificity of observed changes in several novel putative biomarkers, including adenylosuccinate synthase 1, olfactomedin like 3, and glucose-6-phosphate isomerase, we performed technical validation studies using orthogonal mass spectrometry-based techniques as detailed in Methods in the online-only Data Supplement. The representative data in Figure  II in the online-only Data Supplement using aptamer- Proteins found to be increased by >30% within 10 min after planned myocardial injury in both derivation and validation cohorts (global P<1.05E-05 and P<1.33E-04, respectively, for change within 24-h period by 1-way repeated-measures analysis of variance on log-transformed relative fluorescence unit values). Change values denote median percent change. Proteins are listed in alphabetical order.
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enriched multiple-reaction monitoring demonstrates a striking concordance with findings from the expanded aptamer platform and provides accurate quantitation of our protein findings. Table V in the online-only Data Supplement details the peptide sequences, precursor masses, and transition ions selected for multiple-reaction monitoring analysis.
DISCUSSION
We previously reported the application of a 1129-plex aptamer-proteomic assay to individuals undergoing PMI. 1 Here we markedly expanded the scope of prior investigations. While testing the feasibility of large-scale multiplexing with a platform that now measures ≈5000 analytes, we provide novel biological insights into the response to injury in humans. Concordant with the ≈4-fold increased breadth of the platform, we identified ≈3-fold number of new protein changes. It is notable that >75% of our prior aptamer findings 1 were recapitulated in this study with concordant directionality (P<0.05), although here we studied more catheterization controls and excluded many additional proteins that appear to be influenced by heparin treatment. Furthermore, 22 of the proteins described in 2 recent mass spectrometrybased proteomic profiling papers were confirmed using this new technique. 9, 10 An additional ≈150 novel changes were identified in the present investigation.
Compared with the prior iteration of the platform, this version covers a broader array of intracellular proteins (≈30%), many of which are reproducibly identified in human plasma and changed in the setting of MI. We were interested in finding an enrichment of these proteins after MI because 19 of the 33 (58%) most significantly changed proteins are intracellular. Among the novel markers identified in both PMI and SMI, we found many proteins, including coiled-coil-helix-coiled-coil-helix domain-containing 10, dienoyl-CoA reductase 1, and malate dehydrogenase 1and malate dehydrogenase 2, suggesting the release of mitochondrial proteins early after MI. Cysteine-and glycine-rich protein 3, which was increased after SMI and PMI, is hypothesized to mediate cardiac mechanosensation 19 and has been associated with familial-and idiopathicdilated and hypertrophic cardiomyopathy. 20 In addition to identifying low-abundance intracellular proteins not previously assayed in the blood, the expanded platform also provides insight into biologically active proteins that are released after MI. For example, adenylosuccinate synthetase 1 is found in cardiac and skeletal muscle and demonstrates >14-fold increase in circulating levels within 1 hour after MI. This musclespecific enzyme plays a role in purine nucleotide cycle by catalyzing the first step in the conversion of inosine monophosphate to adenosine monophosphate, and mutations in the gene have been reportedly associated with myopathy. 21 Of particular interest are proteins that may have hormone-like functions on other tissues. The mitochondrial ATP synthase-coupling factor 6, the most substantially increased protein (by 10 minutes) after MI, is reported to be a vasoactive peptide. It binds to plasma membrane ATP synthase, leading to vasoconstriction, intracellular acidosis, inhibition of prostacyclin, and nitric oxide generation, resulting in blood pressure elevation. 22 Our study has several limitations. Although this expanded aptamer-based proteomics platform provides broad coverage with high throughput, it is agnostic to Figure. Protein markers that are increased early after the onset of planned myocardial injury (PMI) and in spontaneous myocardial injury (SMI). Data presented are from planned myocardial injury derivation (PMI-D) and PMI validation (PMI-V) cohorts of selected proteins that increased in both derivation (n=20) and validation (n=15) cohorts (P<1.05E-05) and spontaneous myocardial injury (n=63) cohorts (P<6. . P values calculated by 1-way repeated measures analysis of variance performed on log-transformed relative fluorescence unit values. Edges of boxes denote 25th and 75th percentiles, lines denote median, and whiskers are plotted using Tukey method. ****P<0.0001; ***P<0.001; **P<0.01, where P represents significance of change from baseline.
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changes of analytes not targeted. Exclusion of ≈2000 proteins that changed in the catheterization control samples translates into a conservative effort to limit potential confounding factors, possibly excluding proteins that may be changed in MI as well as catheterization. In addition, because groups of proteins cluster within biological pathways, the assumption of independent statistical tests used in our Bonferroni-corrected P values is overly stringent, increasing the possibility of false-negative results. Similarly, although we have emphasized characteristics of individual markers in our derivation and validation analyses, we anticipate that a multimarker approach might ultimately be used clinically. We evaluated temporal covariance as a method to condense the number of proteins for diagnostic value. In a pilot analysis which focused on proteins that were significantly elevated at ≥1 time point from baseline after PMI, we identified 6 temporal protein groupings ( Figure III in the online-only Data Supplement). Carrying forward a subset of proteins with the largest effect size from these groupings (excluding troponin I and CK-MB), we found 39 principal components that accounted for 85% of the variance in the SMI group versus controls. This approach modestly separated the groups with P=0.00077 ( Figure  IV in the online-only Data Supplement). One might hypothesize that specific markers would be most useful when patients are stratified by time to presentation, although this would necessitate future studies in larger numbers of patients. Given that the total number of patients in our cohorts is relatively small, additional samples will also be necessary to identify markers specific to patients with hypertrophic cardiomyopathy or proteins associated with specific medications or clinical traits.
In summary, we demonstrate the feasibility of large-scale aptamer multiplexing at a scale not previously reported. Furthermore, sample throughput of this platform allows one to assess >4800 proteins in hundreds of samples within a week, greatly exceeding the sample throughput approachable by other strategies. To provide additional support of these proof-ofconcept findings, efforts are ongoing aimed at both additional analytic validation using orthogonal techniques as well as clinical validation in large, heterogeneous cohorts.
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